Literature DB >> 7713872

Glutaredoxin accelerates glutathione-dependent folding of reduced ribonuclease A together with protein disulfide-isomerase.

J Lundström-Ljung1, A Holmgren.   

Abstract

Glutaredoxin (Grx) contains a redox-active disulfide and catalyzes thiol-disulfide interchange reactions with specificity for GSH. The dithiol form of Grx reduces mixed disulfides involving GSH or protein disulfides. During oxidative refolding of 8 microM reduced and denatured ribonuclease RNase-(SH)8 in a redox buffer of 1 mM GSH and 0.2 mM GSSG to yield native RNase-(S2)4, a large number of GSH-mixed disulfide species are formed. A lag phase that precedes formation of folded active RNase at a steady-state rate was shortened or eliminated by the presence of a catalytic concentration (0.5 microM) of Escherichia coli Grx together with protein disulfide-isomerase (PDI), its procaryotic equivalent E. coli DsbA, or the PDI analogue the E. coli thioredoxin mutant protein P34H. A mutant Grx in which one of the active site cysteine residues (Cys-11 and Cys-14) had been replaced by serine, C14S Grx, had similar effect compared with its wild-type counterpart. This demonstrated that Grx acted by a monothiol mechanism involving only Cys-11 and that RNase-S-SG-mixed disulfides were the substrates. Grx displayed synergistic activity together with PDI only in GSH/GSSG redox buffers with sufficiently low redox potential (E'0 of -208 or -181 mV) to allow reduction of the active site of Grx. In refolding systems that do not depend on glutathione, like cystamine/cysteamine or in the presence of selenite (SeO3(2-)), no synergistic activity of Grx was observed with PDI. We conclude that Grx acts by reducing mixed disulfides between GSH and RNase that are rate-limiting in enzyme-catalyzed refolding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7713872     DOI: 10.1074/jbc.270.14.7822

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  DsbC activation by the N-terminal domain of DsbD.

Authors:  D Goldstone; P W Haebel; F Katzen; M W Bader; J C Bardwell; J Beckwith; P Metcalf
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

2.  Both platelet- and endothelial cell-derived ERp5 support thrombus formation in a laser-induced mouse model of thrombosis.

Authors:  Freda H Passam; Lin Lin; Srila Gopal; Jack D Stopa; Lola Bellido-Martin; Mingdong Huang; Barbara C Furie; Bruce Furie
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

3.  Polymorphism of the glutathione transferase subunit 3 in Sprague-Dawley rats involves a reactive cysteine residue.

Authors:  T Kumano; J Kimura; M Hayakari; T Yamazaki; D Sawamura; S Tsuchida
Journal:  Biochem J       Date:  2000-09-01       Impact factor: 3.857

4.  Early intermediates in the PDI-assisted folding of ribonuclease A.

Authors:  F Vinci; M Ruoppolo; P Pucci; R B Freedman; G Marino
Journal:  Protein Sci       Date:  2000-03       Impact factor: 6.725

5.  Glutathione-dependent activities of Trypanosoma cruzi p52 makes it a new member of the thiol:disulphide oxidoreductase family.

Authors:  M Moutiez; E Quéméneur; C Sergheraert; V Lucas; A Tartar; E Davioud-Charvet
Journal:  Biochem J       Date:  1997-02-15       Impact factor: 3.857

6.  A glutathione reductase mutant of yeast accumulates high levels of oxidized glutathione and requires thioredoxin for growth.

Authors:  E G Muller
Journal:  Mol Biol Cell       Date:  1996-11       Impact factor: 4.138

7.  Assessment of endoplasmic reticulum glutathione redox status is confounded by extensive ex vivo oxidation.

Authors:  Brian M Dixon; Shi-Hua D Heath; Robert Kim; Jung H Suh; Tory M Hagen
Journal:  Antioxid Redox Signal       Date:  2008-05       Impact factor: 8.401

8.  Functional recovery of diabetic mouse hearts by glutaredoxin-1 gene therapy: role of Akt-FoxO-signaling network.

Authors:  I Lekli; S Mukherjee; D Ray; N Gurusamy; Y H Kim; A Tosaki; R M Engelman; Y-S Ho; D K Das
Journal:  Gene Ther       Date:  2010-02-25       Impact factor: 5.250

9.  De novo design and evolution of artificial disulfide isomerase enzymes analogous to the bacterial DsbC.

Authors:  Silvia Arredondo; Laura Segatori; Hiram F Gilbert; George Georgiou
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

10.  Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose?

Authors:  Nicola Di Santo; Jessie Ehrisman
Journal:  Cancers (Basel)       Date:  2013-09-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.